Hepatitis A Virus Cellular Receptor 2
"Hepatitis A Virus Cellular Receptor 2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An Ig domain-containing membrane receptor that is expressed by TH1 CELLS. It regulates the activation of MACROPHAGES and inhibits TH1-mediated auto- and alloimmune responses to promote IMMUNE TOLERANCE.
| Descriptor ID |
D000072597
|
| MeSH Number(s) |
D12.776.395.550.479 D12.776.543.550.437 D12.776.543.750.830.219
|
| Concept/Terms |
Hepatitis A Virus Cellular Receptor 2- Hepatitis A Virus Cellular Receptor 2
- CD366 Antigen
- Antigen, CD366
- T-Cell Immunoglobulin and Mucin Domain-Containing Protein 3
- T Cell Immunoglobulin and Mucin Domain Containing Protein 3
- TIMD3 Protein
- HAVCR2 Protein
- T-Cell Immunoglobulin Mucin Receptor 3
- T Cell Immunoglobulin Mucin Receptor 3
|
Below are MeSH descriptors whose meaning is more general than "Hepatitis A Virus Cellular Receptor 2".
Below are MeSH descriptors whose meaning is more specific than "Hepatitis A Virus Cellular Receptor 2".
This graph shows the total number of publications written about "Hepatitis A Virus Cellular Receptor 2" by people in this website by year, and whether "Hepatitis A Virus Cellular Receptor 2" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2007 | 0 | 1 | 1 |
| 2010 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
| 2013 | 0 | 2 | 2 |
| 2017 | 3 | 0 | 3 |
| 2019 | 0 | 3 | 3 |
| 2020 | 0 | 3 | 3 |
| 2021 | 2 | 3 | 5 |
| 2022 | 1 | 5 | 6 |
| 2023 | 0 | 4 | 4 |
| 2024 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Hepatitis A Virus Cellular Receptor 2" by people in Profiles.
-
CAR-redirected natural killer T cells demonstrate superior antitumor activity to CAR-T cells through multimodal CD1d-dependent mechanisms. Nat Cancer. 2024 Nov; 5(11):1607-1621.
-
Pediatric glioma immune profiling identifies TIM3 as a therapeutic target in BRAF fusion pilocytic astrocytoma. J Clin Invest. 2024 Aug 13; 134(19).
-
The rise of TIM-3: A promising immune target in diffuse midline gliomas. Clin Transl Med. 2024 01; 14(1):e1536.
-
Galectin-3 predicts acute GvHD and overall mortality post reduced intensity allo-HCT: a BMT-CTN biorepository study. Bone Marrow Transplant. 2024 Mar; 59(3):334-343.
-
Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromes. Am J Hematol. 2024 02; 99(2):E32-E36.
-
TIM-3 blockade in diffuse intrinsic pontine glioma models promotes tumor regression and antitumor immune memory. Cancer Cell. 2023 11 13; 41(11):1911-1926.e8.
-
Non-viral TRAC-knocked-in CD19KICAR-T and gp350KICAR-T cells tested against Burkitt lymphomas with type 1 or 2 EBV infection: In vivo cellular dynamics and potency. Front Immunol. 2023; 14:1086433.
-
mTOR regulates T cell exhaustion and PD-1-targeted immunotherapy response during chronic viral infection. J Clin Invest. 2023 01 17; 133(2).
-
Evolution and modulation of antigen-specific T cell responses in melanoma patients. Nat Commun. 2022 10 11; 13(1):5988.
-
Phase II study of durvalumab (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC). J Immunother Cancer. 2022 08; 10(8).